9 Meters Biopharma, Inc. (NMTRQ)

0.0001 0.0000 (0.00%) At close: 11:04AM EDT

9 Meters Biopharma, Inc.

4509 Creedmoor Road
Suite 201
Raleigh, NC 27612
United States
919 275 1933
https://www.9meters.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Peter H. R. Green M.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Mr. Joseph A. Murray M.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Ciaran P. Kelly M.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Elena Verdu M.D., Ph.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Mr. Markku Mäki M.D., Ph.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. William J. Sandborn M.D., Ph.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	1963
Dr. Roger Liddle M.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Anthony J. Dimarino Jr.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Brian Gordon Feagan FRCPC, M.D., M.P.H.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Aida Habtezion M.D., M.Sc.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Corporate governance

9 Meters Biopharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.